- Emergent BioSolutions has signed a multi-year agreement worth approximately $50 million with SAB Biotherapeutics to support development and manufacturing of SAB-142.
- The agreement includes process development, clinical manufacturing, and potential commercial supply, with $36 million tied to regulatory and milestone achievements.
Emergent BioSolutions Inc. has entered into a multi-year agreement with SAB Biotherapeutics, Inc. to support the process development and manufacturing of SAB-142, a clinical-stage programme targeting autoimmune type 1 diabetes. The agreement is valued at approximately $50 million, with $36 million contingent on future regulatory approval and downstream milestones.
Under the terms of the agreement, Emergent will provide end-to-end CDMO services, including process development and scale-up, technology and analytical method transfer, and manufacturing support for ongoing clinical studies. The scope also includes commercial manufacturing services, subject to regulatory approval.
The work will be carried out at Emergent’s facility in Winnipeg, Manitoba, which will serve as the primary site for development and manufacturing of bulk process intermediate and drug product for SAB-142. The facility is used for plasma-derived and complex biologic manufacturing.
“Emergent is pleased to leverage our specialised manufacturing capabilities to support the advancement of SAB-142.”
Bill Hartzel, senior vice president, manufacturing and bioservices at Emergent BioSolutions
The agreement reflects the companies’ focus on supporting the development of SAB-142 through integrated contract manufacturing capabilities and scalable production to meet potential future demand.
